But Paxlovid and molnupiravir will be available only at certain Walmart and Sam’s Club locations.
Walmart and Sam’s Club pharmacies are ready to receive and dispense Paxlovid and Molnupiravir, antiviral medications to treat COVID-19, in certain areas.
On December 23, the FDA issued an emergency use authorization (EUA) for Merck’s molnupiravir to treat mild-to-moderate COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing who are at high risk for progression to severe COVID-19 and for those whom for alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate, the agency said in a statement. Molnupiravir was originally going to be a treatment flu, but researchers at the Emory Institute for Drug Development in Atlanta shifted gears and developed it as a treatment for COVID-19
A day before the EUA for molnupiravir, the agency issued an EUA for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) to treat mild-to-moderate COVID-19 in adults and pediatric patients.
Both antivirals are available by prescription only. Last summer, the Biden administration announced a plan that involves plowing $3.2 billion into research of antivirals as treatments for COVID-19.
Paxlovid and Molnupiravir will only be available at certain Walmart and Sam’s Club locations in a limited number of states until more supply is available, Walmart said in a statement.
Walmart worked closely with the federal government and state health departments to select locations where states determined the treatment was needed most, according to the retailer.
“While initial medication supply is limited, Walmart and Sam’s Club pharmacies stand ready to help expand treatment access nationwide,” the company said.
“We are committed to working with our state and federal partners to provide access to new treatment options like authorized COVID-19 antiviral medications, as they become available,” said Kevin Host, senior vice president of pharmacy at Walmart. “This medication offers customers the option to recover at home and helps reduce the burden on our hospitals and communities.”
Customers and healthcare providers can go to walmart.com/covidmedication to find the nearest store or club that is carrying the medication and to send the electronic prescription.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More
2 Commerce Drive
Cranbury, NJ 08512